Finally, supported by epidemiological findings showing that high levels of IgE might confer protection against certain cancer types and considering the broad effector responses triggered by IgE on different cell types (including mast cells, basophils, neutrophils, eosinophils, macrophages or monocytes), the use of IgE-based therapeutic strategies targeting specific tumor antigens has been proposed as a potential novel strategy to complement the already established IgG class antibodies [299, 309]. This evidence concerns the gene IGHE and neoplasm.